[go: up one dir, main page]

PE20090765A1 - METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS - Google Patents

METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS

Info

Publication number
PE20090765A1
PE20090765A1 PE2008000970A PE2008000970A PE20090765A1 PE 20090765 A1 PE20090765 A1 PE 20090765A1 PE 2008000970 A PE2008000970 A PE 2008000970A PE 2008000970 A PE2008000970 A PE 2008000970A PE 20090765 A1 PE20090765 A1 PE 20090765A1
Authority
PE
Peru
Prior art keywords
seq
antibody
amino acid
cancer cells
compositions
Prior art date
Application number
PE2008000970A
Other languages
Spanish (es)
Inventor
Peter Flynn
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20090765A1 publication Critical patent/PE20090765A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

REFERIDO A UN ANTICUERPO O FRAGMENTO FAB`, QUE SE ENLAZA AL RECEPTOR DE MUERTE 5 (DR5), Y QUE INDUCEN LA APOPTOSIS DE CELULAS CANCEROSAS, DICHO ANTICUERPO POSEE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE UN SEGMENTO V POR LO MENOS 90% IDENTICA A LA SEC ID NO:44, UN CDR3 QUE COMPRENDE LA SECUENCIA AMINOACIDA HEEGI (SEC ID NO: 49); Y UN FR4 QUE ES UNA LINEA GERMINAL HUMANA JH4 Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE UN SEGMENTO V POR LO MENOS 90% IDENTICO A LA SEC ID NO: 46 O SEC ID NO:48, UN CDR3 QUE COMPRENDE LA SECUENCIA AMINOACIDA QXHXXTP (SEC ID NO:50), EN DONDE X REPRESENTA CUALQUIER AMINOACIDO Y UN FR4 QUE ES UNA LINEA GERMINAL HUMANA JK2. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO. SIENDO UTIL PARA EL TRATAMIENTO DE DESORDENES HIPERPROLIFERATIVOS QUE INCLUYEN CANCER TAL COMO: CARCINOMAS, GLIOMAS, MESOTELIOMAS, MELANOMAS, LINFOMAS, LEUCEMIASREFERRED TO AN ANTIBODY OR FAB` FRAGMENT, WHICH IS LINKED TO DEATH RECEPTOR 5 (DR5), AND WHICH INDUCES THE APOPTOSIS OF CANCER CELLS, SUCH ANTIBODY HAS: A) A VARIABLE REGION OF HEAVY CHAIN THAT INCLUDES AT LEAST ONE SEGMENT V 90% IDENTICAL TO SEQ ID NO: 44, A CDR3 INCLUDING THE AMINO ACID SEQUENCE HEEGI (SEQ ID NO: 49); AND AN FR4 WHICH IS A HUMAN GERM LINE JH4 AND B) A LIGHT CHAIN VARIABLE REGION THAT INCLUDES A SEGMENT V AT LEAST 90% IDENTIFIC TO SEQ ID NO: 46 OR SEQ ID NO: 48, A CDR3 THAT INCLUDES THE AMINO ACID SEQUENCE QXHXXTP (SEQ ID NO: 50), WHERE X REPRESENTS ANY AMINO ACID AND AN FR4 WHICH IS A JK2 HUMAN GERMINAL LINE. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT CONTAINS SUCH ANTIBODY. BEING USEFUL FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS THAT INCLUDE CANCER SUCH AS: CARCINOMAS, GLIOMAS, MESOTHELIOMAS, MELANOMAS, LYMPHOMAS, LEUKEMIAS

PE2008000970A 2007-06-08 2008-06-06 METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS PE20090765A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94286207P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
PE20090765A1 true PE20090765A1 (en) 2009-07-10

Family

ID=39730803

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000970A PE20090765A1 (en) 2007-06-08 2008-06-06 METHODS AND COMPOSITIONS TO INDUCE APOPTOSIS IN CANCER CELLS

Country Status (4)

Country Link
AR (1) AR066913A1 (en)
PE (1) PE20090765A1 (en)
TW (1) TW200911835A (en)
WO (1) WO2008154439A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377443B2 (en) 2010-08-27 2013-02-19 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
US9550836B2 (en) * 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
EA201491599A1 (en) * 2012-02-29 2015-05-29 Джилид Байолоджикс, Инк. ANTIBODIES TO MATRIX METALLOPROTEINASE 9
CN106397594B (en) * 2016-10-25 2019-06-04 中国药科大学 A fully human anti-human death receptor 5 agonist single-chain antibody and its application

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
MXPA05000511A (en) * 2001-07-12 2005-09-30 Jefferson Foote Super humanized antibodies.
CA2507077A1 (en) * 2002-11-27 2004-06-17 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
WO2005069970A2 (en) * 2004-01-20 2005-08-04 Kalobios, Inc. Antibody specificity transfer using minimal essential binding determinants
KR20070010046A (en) * 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 antibody and uses thereof

Also Published As

Publication number Publication date
AR066913A1 (en) 2009-09-23
TW200911835A (en) 2009-03-16
WO2008154439A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
AR117913A2 (en) DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES
PE20150212A1 (en) ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND THEIR DERIVATIVES
MX2009002054A (en) Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases.
CL2008000789A1 (en) COMPOUNDS DERIVED FROM ADENINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS, USEFUL TO TREAT ALLERGIC, VIRAL OR CANCER DISEASES, AMONG OTHERS.
CY1117563T1 (en) HER3 PARTS AND USE OF THESE
PE20140247A1 (en) ANTI-CD38 ANTIBODIES
EA201300242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES
PE20121397A1 (en) SPECIFIC ANTIBODIES FOR CHAIN-17
BRPI0513310A (en) tetrapeptide analogs
CY1116264T1 (en) ANTIBODIES AGAINST HUMAN VASCULAR 2
CL2008003788A1 (en) Pharmaceutical composition comprising a) the humanized b-ly1 antibody (anti-cd20 / human b-lymphocyte / bp35 restricted referencing antigen, type ii), b) optionally from 0.001% to 1% w / v of at least one surfactant, and c) 1 to 100 mm of a buffer; use to treat cd20-related diseases.
CY1115639T1 (en) SPECIAL RACE DEATH SUBSCRIPTIONS
CO6231039A2 (en) COMPOSITIONS THAT INCLUDE ANTIBODY THAT IS SET TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
CY1120536T1 (en) METHOD AND COMPOSITIONS FOR CANCER HEALTH EDUCATION
AR062268A1 (en) BINDING AGENTS DIRECTED TO PDGFR-ALFA AND ITS USES
UY32926A (en) COMPOUNDS AS ANTAGONISTS OF LISOPHOSPHATIDIC ACID RECEPTORS
PE20140230A1 (en) ANTIBODIES TO THE EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
CL2009000402A1 (en) Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others.
EA201100691A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
PE20091655A1 (en) DRUG FOR LIVER CANCER
DOP2002000545A (en) SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
UY30220A1 (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal